Dr. Pandey needs to tell his story. We should contact a Wall Street Journal reporter and have him contact Pandey. I think this is a better approach than calling a lawyer or the SEC. I don't think we're at that stage yet and hope we do not get there.
I've been through this scenario before with other stocks. Litigation seldom works for shareholders. Let's give them the benefit of the doubt. I think they are still in the process of familiarizing themselves with the business and working on the lawsuit at the same time. They are also in the process of finding a CEO for the company as well as preparing to file IND for Hemoxin and 5-HMF and maybe an IPO.
I am counting on Basu to turn this company around to his benefit and to the benefit of XKEM shareholders.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.